Teva to Acquire Barr
Patent Docs: By Sherri Oslick — In a transaction merging two major players in the generic pharmaceutical arena, Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced late last week that they have entered into an agreement by which Teva will acquire Barr for $7.46 billion plus the assumption of $1.5 billion in debt. The transaction is expected to close by the end of 2008, pending antitrust clearance and Barr stockholder approval. Barr Pharmaceuticals, Inc., a holding company, operates through subsidiaries Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc., and PLIVA d.d. and its subsidiaries. Teva is the leading generic pharmaceutical company worldwide, and…